Miller-Rich v. Altum Pharmaceuticals Inc.

CourtDistrict Court, S.D. New York
DecidedApril 16, 2024
Docket1:22-cv-03473
StatusUnknown

This text of Miller-Rich v. Altum Pharmaceuticals Inc. (Miller-Rich v. Altum Pharmaceuticals Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Miller-Rich v. Altum Pharmaceuticals Inc., (S.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK NANCY MILLER-RICH, Plaintiff, -against- Case No. 1:22-cv-03473 (JLR) ALTUM PHARMACEUTICALS INC., BETTERLIFE PHARMA INC., AHMAD OPINION AND ORDER DOROUDIAN, STEPHEN DATTELS, KRISZTIAN TOTH, JOSEPH MIMRAN, JOHN AND JANE DOES 1-50, and ABC CORPORATIONS 1-20, Defendants. JENNIFER L. ROCHON, United States District Judge: Nancy Miller-Rich (“Plaintiff”) moves for reconsideration of Miller-Rich v. Altum Pharmaceuticals Inc., No. 22-cv-03473 (JLR), 2023 WL 8187875 (S.D.N.Y. Nov. 27, 2023) (“Miller-Rich I”). ECF No. 82 (“Recon. Br.”). For the reasons set forth below, the Court denies Plaintiff’s motion. BACKGROUND The Court generally assumes the parties’ familiarity with Plaintiff’s allegations and the procedural history, as recounted in Miller-Rich I, and discusses only those details necessary to explain its decision here. See 2023 WL 8187875, at *2-5; see also ECF No. 50-1 (the “Consulting Agreement” or “Consult. Ag.”); ECF No. 50-2 (the “Employment Agreement” or “Emp. Ag.”); ECF No. 50-3 at 1-5 (the “Settlement Agreement” or “Set. Ag.”); ECF No. 50-3 at 8-13 (the “Release” or “Rel.”).1

1 Miller-Rich I accurately referred to the Release as a “schedule” appended to the Settlement Agreement. See, e.g., 2023 WL 8187875, at *3. Here, the Court refers to it as the “Release” to reflect the terminology used by Plaintiff in her briefs on the motion for reconsideration. On April 28, 2022, Plaintiff initiated this action against Altum Pharmaceuticals Inc. (“Altum”), BetterLife Pharma Inc. (“BetterLife”), Ahmad Doroudian, Stephen Dattels, Krisztian Toth, Joseph Mimran, John and Jane Does 1-50 (the “Does”), and ABC Corporations 1-20 (the “Corporations” and, collectively, “Defendants”). ECF No. 1. Plaintiff asserted five claims in the operative complaint. ECF No. 50 (the “Amended Complaint” or “Am. Compl.”). First, Plaintiff alleged that Altum and Doroudian engaged in federal

securities fraud, and that “Plaintiff relied on defendants’ representations in continuing to remain employed at Altum and discharge her obligations under the Employment Agreement.” Id. ¶¶ 78-81 (“Claim I”); see also id. ¶ 42. Second, Plaintiff alleged that all Defendants engaged in common-law fraud by making misrepresentations in various public statements, and that “Plaintiff reasonably relied on these misrepresentations in tendering her Altum shares in connection with the [merger between Altum and BetterLife].” Id. ¶¶ 82-88 (“Claim II”); see also id. ¶ 73. Third, Plaintiff alleged that Altum and Doroudian engaged in common-law fraud, and that “Plaintiff reasonably relied on the[ir] misrepresentations in continuing her employment with Altum.” Id. ¶¶ 89-95 (“Claim III”). Fourth, Plaintiff alleged that Altum breached the Employment Agreement. Id. ¶¶ 96-102 (“Claim IV”). Fifth, Plaintiff alleged

that Altum breached the Settlement Agreement. Id. ¶¶ 103-110 (“Claim V”). Altum, BetterLife, Doroudian, and Dattels (collectively, the “Appearing Defendants”) appeared and waived any potential objections to service of process. ECF Nos. 14, 16, 18, 21. Although Plaintiff requested the issuance of summonses for Mimran and Toth, ECF Nos. 56- 57, Plaintiff never submitted proof of service of process for Toth, Mimran, the Does, or the Corporations (collectively, the “Non-Appearing Defendants”), and none of the Non- Appearing Defendants has appeared.2 In Miller-Rich I, the Court granted the Appearing Defendants’ motions to dismiss the Amended Complaint on the ground of forum non conveniens. See 2023 WL 8187875, at *8- 13.3 On December 11, 2023, Plaintiff moved for reconsideration of that decision. Recon. Br.

2 Plaintiff reports that she is seeking to serve Toth and Mimran under the Hague Convention. ECF No. 88. Plaintiff has not moved the Court to authorize alternative service.

3 In Miller-Rich I, the Court stated that it was granting the Appearing Defendants’ motions to dismiss, and it ordered the Clerk of Court to close the case. See 2023 WL 8187875, at *13. Now having the opportunity to do so, the Court wishes to clarify the basis for dismissal of the claims against the Non-Appearing Defendants. As several courts in this District have held, when a court grants a served defendant’s motion to dismiss (including on grounds of forum non conveniens), the court may also dismiss claims against an unserved defendant sua sponte where “the same points control the claims against [the unserved defendant].” Virtual Dates, Inc. v. Afternic.com, Inc., No. 01-cv-04023 (LAK), 2001 WL 1646451, at *2 (S.D.N.Y. Dec. 20, 2001); see, e.g., Star Colbert v. Dougan, No. 23-cv-07297 (CM), 2024 WL 1197863, at *25 (S.D.N.Y. Mar. 20, 2024) (“Several of the Defendants . . . have not been served with process in this case and did not join in the motion to dismiss. Nevertheless, dismissal of the claim against them is warranted because the Court’s holdings above necessarily establish the inadequacy of the Complaint as to them. Accordingly, Plaintiffs’ Swiss law claim against the unserved Defendants is dismissed on forum non conveniens grounds.” (brackets, quotation marks, and citations omitted)); Cartwright v. D’Alleva, No. 17-cv-05953 (AT), 2018 WL 9343524, at *9 (S.D.N.Y. Aug. 27, 2018) (“[The Unserved Defendants] have not been served with process in this case, and did not, therefore, join the Moving Defendants’ motion to dismiss. The same grounds for dismissal of the Moving Defendants, however, warrant dismissal of the Amended Complaint as to the Unserved Defendants. Accordingly, the Amended Complaint is DISMISSED with respect to the Unserved Defendants.”), aff’d, 782 F. App’x 77 (2d Cir. 2019) (summary order); Banco De Serguros Del Estado v. J.P. Morgan Chase & Co., 500 F. Supp. 2d 251, 265 n.18 (S.D.N.Y. 2007) (“[T]he non-moving Defendants have not been served. However, even had they been served and even in the more unlikely event that the Court had found that it had personal jurisdiction over them, it would still dismiss the case against them on the ground of forum non conveniens.”). The Court thus dismisses the claims against the Non-Appearing Defendants “for the same reasons applicable to [the Appearing Defendants],” Curry v. Kim, No. 22-cv-04127 (PMH), 2023 WL 7625859, at *6 n.8 (S.D.N.Y. Nov. 14, 2023): namely, that either through enforcement of the Release’s forum-selection clause or under the conventional three-part analysis, this case should be dismissed for forum non conveniens. Defendants opposed Plaintiff’s motion on December 22, 2023. ECF No. 83 (“Recon. Opp.”). Plaintiff replied on December 29, 2023. ECF No. 86 (“Recon. Reply”). LEGAL STANDARD “A motion for reconsideration is an extraordinary request that is granted only in rare circumstances.” Van Buskirk v. United Grp. of Cos., 935 F.3d 49, 54 (2d Cir. 2019). Such a motion “is not a vehicle for relitigating old issues, presenting the case under new theories, securing a rehearing on the merits, or otherwise taking a second bite at the apple.” Analytical

Survs., Inc. v. Tonga Partners, L.P., 684 F.3d 36, 52 (2d Cir. 2012) (quotation marks and citation omitted). “[R]econsideration will generally be denied unless the moving party can point to controlling decisions or data that the court overlooked – matters, in other words, that might reasonably be expected to alter the conclusion reached by the court.” Van Buskirk, 935 F.3d at 54 (citation omitted). DISCUSSION The Court adheres to its decision that the Release’s forum-selection clause applies to all of Plaintiff’s claims, thus warranting forum non conveniens dismissal. See Miller-Rich I, 2023 WL 8187875, at *8-13.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Scherk v. Alberto-Culver Co.
417 U.S. 506 (Supreme Court, 1974)
Piper Aircraft Co. v. Reyno
454 U.S. 235 (Supreme Court, 1982)
Marra, Rosemarie v. Papandreou, Vaso
216 F.3d 1119 (D.C. Circuit, 2000)
Global Seafood Inc. v. Bantry Bay Mussels Ltd.
659 F.3d 221 (Second Circuit, 2011)
Palazzo v. Corio
232 F.3d 38 (Second Circuit, 2000)
Analytical Surveys, Inc. v. Tonga Partners, L.P.
684 F.3d 36 (Second Circuit, 2012)
Monster Daddy, LLC v. Monster Cable Products, Inc.
483 F. App'x 831 (Fourth Circuit, 2012)
Lust v. Nederlandse Programma Stichting
501 F. App'x 13 (Second Circuit, 2012)
Magi XXI, Inc. v. Stato della Città del Vaticano
714 F.3d 714 (Second Circuit, 2013)
Alfadda v. Fenn
966 F. Supp. 1317 (S.D. New York, 1997)
Banco De Seguros Del Estado v. J.P. Morgan Chase & Co.
500 F. Supp. 2d 251 (S.D. New York, 2007)
Phillips v. Audio Active Ltd.
494 F.3d 378 (Second Circuit, 2007)
Cfirstclass Corp. v. Silverjet Plc
560 F. Supp. 2d 324 (S.D. New York, 2008)
Federal Insurance v. Allstate Insurance
341 A.2d 399 (Court of Appeals of Maryland, 1975)

Cite This Page — Counsel Stack

Bluebook (online)
Miller-Rich v. Altum Pharmaceuticals Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/miller-rich-v-altum-pharmaceuticals-inc-nysd-2024.